FindTrial
Sign In

Intra-operative opioids versus opioid-free anesthetic effects on immune function and tumor biology in patients with colorectal cancer undergoing laparoscopic abdominal surgery: a prospective, single-blind, randomized controlled, single-center trial

Intra-operative opioids versus opioid-free anesthetic effects on immune function and tumor biology in patients with colorectal cancer undergoing laparoscopic abdominal surgery: a prospective, single-blind, randomized controlled, single-center trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058202
Enrollment
Unknown
Registered
2022-04-01
Start date
2022-03-30
Completion date
Unknown
Last updated
2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Intra-operative opioids with inhalation anaesthesia group:
Opioid-free with inhalation anaesthesia group:
Intra-operative opioids with total intravenous anaesthesia group:
Opioid-free with total intravenous anaesthesia group:

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Primary patients aged 18-79 years who received elective laparoscopic resection for primary intestinal cancer; 2. Duration of operation and general anesthesia >= 2 hours, postoperative hospital stay >= 3 days; 3. Patients participate voluntarily and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Other treatments, such as surgery, chemoradiotherapy and immunotherapy, have been performed before surgery; 2. Previous or current history of other systemic tumors, such as lung cancer; 3. Taking sedative, anti-depressant or hormone medications, or allergic to local anesthetics and other medications; 4. Patients with no long-term follow-up or poor compliance; 5. Poor general condition, combined with a history of severe cardiovascular system, respiratory system, liver and kidney system, central nervous system diseases, may not survive for more than 3 months; 6. Unable to cooperate with follow-up or poor compliance; 7. Preoperative blood pressure was poorly controlled, with preoperative blood pressure base value > 180/100 mmHg; 8. Patients who had participated in the study (patients who required a second surgery during the study).

Design outcomes

Primary

MeasureTime frame
Determination of innate immune function of neutrophils;Citrullinated histone H3, H3Cit;—

Secondary

MeasureTime frame
myeloperoxidase (MPO);Quality of recovery (QoR-15) score;stress response (ACTH, cortisol);Perioperative related clinical factors;Tumor metastasis markers;Angiogenic markers;—

Countries

China

Contacts

Public ContactDongtai Chen

Sun Yat-sen University Cancer Center

chendt@sysucc.org.cn+86 13631373862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026